Found 7 matching trials
Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery
PHASE3The primary objective is to evaluate the efficacy of once daily (QD) subcut...
Location
Sanofi-Aventis Administrative Office
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
PHASE3The primary objective was to compare the efficacy of once daily \[q.d\] sub...
Location
Sanofi-Aventis Administrative Office
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
PHASE2The primary objective was to demonstrate the dose-response of Semuloparin s...
Location
Sanofi-Aventis Administrative Office
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
PHASE3The primary objective was to compare the efficacy of Semuloparin sodium (AV...
Location
Sanofi-Aventis Administrative Office
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
PHASE3The primary objective was to compare the efficacy of once daily \[q.d.\] su...
Location
Sanofi-Aventis Administrative Office
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
PHASE3The primary objective was to compare the efficacy of once daily subcutaneou...
Location
Investigational Site Number 840006
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
PHASE3The primary objective is to compare the efficacy and safety of once daily (...
Location
Investigational Site Number 840026